Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cogent Biosciences, Inc. (COGT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $33,08, with a market capitalisation of $5,80B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11,60 to $43,73. This page covers its latest market performance, valuation, price trends and company information.
$5,80B | |
$32,77 | |
$153,00 | |
$3,67 | |
$32,74 | |
60,00 | |
2,27M | |
-- | |
$43,73 | |
$11,60 | |
-- | |
-- |
Cogent Biosciences, Inc. (COGT) is trading at $33,08 in pre-market trading as of 2026-09-16 08:32:00, up 1,04% ($0,34) from the previous close of $32,74
Pre-market trading shows how investors are pricing COGT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Cogent Biosciences, Inc. (COGT) moved from $34,76 to $33,08, representing a decline of 4,83% ($1,68).
The stock traded between $32,69 and $35,75 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1,68 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 66,9%
COGT is currently trading at $33,08, placing it 66,9% of the way from its 52-week low of $11,60 to its 52-week high of $43,73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 258 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cogent Biosciences, Inc. (COGT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.